KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Clover Health Investments (CLOV) Other Non-Current Liabilities (2020 - 2025)

Clover Health Investments' Other Non-Current Liabilities history spans 6 years, with the latest figure at $6.6 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 560.0% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $6.6 million, up 560.0%, while the annual FY2025 figure was $6.6 million, 560.0% up from the prior year.
  • Other Non-Current Liabilities reached $6.6 million in Q4 2025 per CLOV's latest filing, down from $25.3 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $62.0 million in Q1 2021 to a low of $1.0 million in Q4 2024.
  • Average Other Non-Current Liabilities over 5 years is $19.7 million, with a median of $16.2 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 91.35% in 2023, then soared 560.0% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $14.1 million in 2021, then increased by 14.88% to $16.2 million in 2022, then plummeted by 91.35% to $1.4 million in 2023, then fell by 28.57% to $1.0 million in 2024, then skyrocketed by 560.0% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for CLOV's Other Non-Current Liabilities are $6.6 million (Q4 2025), $25.3 million (Q3 2025), and $28.9 million (Q2 2025).